Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new […]

ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP Delivery of ANGPTL3 Base Editor Led to Potent Editing in both LDLR-Deficient and Normal NHP Livers, Supporting Potential Broad Applicability CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE […]